DUTASTERIDE 0.5mg. IP + TAMSULOSIN 0.4mg. IP

A fixed-dose combination of 5α-reductase inhibitor and Alpha (1)-adrenergic receptor antagonist that treats benign prostatic hyperplasia and an enlarged prostate in men. (Keating, 2012) Relaxes the smooth muscle of the prostate and bladder neck without affecting the detrusor muscle of the bladder wall. (J Miller, 2009) Decreases the resistance to urine flow without compromising bladder contractility. (J Miller, 2009) Achieves significant improvement in the symptoms, flow rate, quality of life, and improves treatment satisfaction as compared to tamsulosin monotherapy. (B-H Chung, 2009) A well-tolerated treatment in patients with symptomatic benign prostatic hyperplasia. (Keating G. M., 2012) Improves the lower urinary tract symptoms to a significantly greater extent than dutasteride or tamsulosin. (Keating G. M., 2012) Provides significantly greater improvements in patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia symptoms. (Jack Barkin, 2009) Offers faster and more profound symptom reduction in men with moderate symptoms of benign prostatic hyperplasia at risk of progression. (Claus G. Roehrborn, 2015)